North Carolina · Nonprofit
Society for Translational Oncology
Society for Translational Oncology (North Carolina) receives grants from 2 organizations whose IRS filings report $310,000 to it, the largest being AlphaMed Cancer Foundation ($285,000). 1 of them have funded it in more than one year.
- Revenue FY2025
- $289k
- Funders on record
- 2
- Grants received
- $310k
- Net assets
- $1.2M
What Society for Translational Oncology does
Mission
Global Mission The Society for Translational Oncology (STO), a 501(c)(3) not-for-profit organization, is dedicated to advancing global oncology and improving patient care by bridging the gap between scientific discovery and clinical application. Our mission is to promote high-quality, equitable healthcare through innovative education and collaborative global efforts. STO empowers healthcare professionals with the knowledge and tools to implement cutting-edge cancer therapies and improve patient outcomes worldwide. Through strategic guidance and global alliances, we work to harmonize cancer clinical trials and regulatory standards, ensuring that life-saving treatments are speedily accessible to all patients with cancer. Continuing Medical Education Mission STO is committed to providing impactful education to oncology physicians, with the goal of improving the quality and safety of care for patients with cancer. This mission will be fulfilled by offering relevant and effective continuing medical education programs, focusing on: Knowledge and strategies for implementation of critical new developments in cancer treatment, screening, and prevention, the translational gap between…
As stated on its FY2025 Form 990.
Programs
HARMONY is a global initiative advancing equitable cancer care by improving alignment across clinical research, regulatory pathways and implementation. In response to persistent disparities in access to cancer prevention, screening and treatment, HARMONY convenes international stakeholders to reduce fragmentation, strengthen collaboration and accelerate the translation of evidence into practice. Current activities focus on cervical cancer, a largely preventable disease that causes disproportionate mortality in low-resource and underserved settings. HARMONY supports harmonized approaches to clinical trials and implementation research, promotes equitable access to evidence-based interventions (HPV screening and early detection), and builds collaborative networks to advance sustainable, scalable solutions. Collectively, these efforts aim to ensure that innovations in cervical cancer prevention and care reach populations most at risk and contribute to global elimination goals.
$87,207 spent41% of program spendingMolecular testing is a foundational element of personalized medicine. Understanding and overcoming challenges in implementing best practice guidelines for molecular testing can support better diagnosis and guide treatment decisions. "Incorporating Molecular Testing to Support Personalized Cancer Care" is a three-part educational program that focuses on the adoption of best practice guidelines and incorporating evidence from an MD Anderson Cancer Network Performance Improvement and Quality Improvement (PI/QI) program (a program of The University of Texas MD Anderson Cancer Center). Piloted at two Cancer Network sites, this PI/QI program aimed to optimize the use of molecular testing in thyroid and lung cancers.
$38,818 spent18% of program spendingThe Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization that promotes high-quality, equitable patient care and fosters the discovery and clinical translation of important new therapies that enhance the practice of global oncology as well as supports the prevention and treatment of infectious diseases that impact cancer patients and others with weakened immune systems, thus helping protect the vulnerable from life-threatening infections. STO bridges a translational gap between drug discovery and approved drug delivery with a portfolio of educational activities for physicians and other members of the healthcare team. STO's decades-long commitment to translational research and education includes fellowships in both cancer and infectious diseases. The latter has become a critical STO commitment during the COVID-19 pandemic from the global genesis to worldwide distribution of new vaccines and improved therapeutics. STO is committed to diversity, inclusivity, and equity throughout our programs.
$86,312 spentof which $1,563 as grants41% of program spending
The 3 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $212,337.
The organization over time
Each line starts at 100 in 2020, so what you read is the shape rather than the size: 150 means half as much again as 2020, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $746k to $1.4M (+83%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2021 2%. Grants only. Government contracts and fees sit inside program revenue.
58% of Society for Translational Oncology’s revenue is contributions — about as donation-reliant as the typical peer (82% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 6 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Ann Murphy PHD
Executive Director
Board chair
Martin J Murphy DMEDSC PHD FASCO
Chairman
As listed on its FY2025 Form 990.
Who funds it, year by year
2019 → 2023: the base held at 1 funder, grant income fell $110k → $25k.
1 of 2 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 8% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of Society for Translational Oncology’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
Society for Translational Oncology leans on a few funders — its largest provides 92% of grant income and the top three 100%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
Largest funder’s share by year: 2019 100% · 2020 100% · 2023 100% — broadly stable.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
100% of Society for Translational Oncology's grant income comes from North Carolina funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $25k arriving through sponsors registered in 1 state is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
Society for Translational Oncology receives grants from 2 organizations whose IRS filings report $310k to it.
this organization peer median middle 50% of peers· 7,883 health nonprofits $100k–$1M, FY2025
Organizations like Society for Translational Oncology
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In North Carolina
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
40% of spending goes to programs.
Governance
Public support
73%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Part of a family of 1 related entity
- AlphaMed Consulting Inc · corp_trust
Screen this organization
A dated, signed PDF of the compliance screen for Society for Translational Oncology: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds Society for Translational Oncology?
- Society for Translational Oncology (North Carolina) receives grants from 2 organizations whose IRS filings report $310,000 to it, the largest being AlphaMed Cancer Foundation ($285,000). 1 of them have funded it in more than one year.
- How many funders does Society for Translational Oncology have?
- IRS filings report 2 organizations giving $310,000 in grants to Society for Translational Oncology, 1 of which have funded it in more than one year.
- Who is the largest funder of Society for Translational Oncology?
- AlphaMed Cancer Foundation is the largest funder on record, with $285,000 in grants. The full list of funders is on this page.
- How can an organization like Society for Translational Oncology find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in North Carolina. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
Play a game about who funds Society for Translational Oncology →
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2020–2025), and the filings of 2 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing